🏛️ Verified NIH Record • Updated 2026-08-07
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) (NCT07161037)
A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects With Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Vertex Pharmaceuticals Incorporated
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407.
Who can join: Review the eligibility criteria below.
Location: Alabama Kidney Research — Alabaster, Alabama
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (43 Sites)
Showing the first 25 of 43 sites.
- Alabama Kidney Research — Alabaster, Alabama
- UAB Nephrology Research at CH19 — Birmingham, Alabama
- Kaiser Permanente Los Angeles Medical Center — Los Angeles, California
- UCSF Clinical Research Center at Parnassus — San Francisco, California
- Nephrology & Hypertension Associates, PC — Middlebury, Connecticut
- Yale University - Yale Nephrology Clinical Research Clinic — New Haven, Connecticut
- Mayo Clinic - Jacksonville — Jacksonville, Florida
- Emory School of Medicine - Renal Division — Atlanta, Georgia
- Renal Associates — Columbus, Georgia
- UChicago Medicine - Duchossois Center for Advanced Medicine - Nephrology — Chicago, Illinois
- University of Iowa Health Care Medical Center- Nephrology — Iowa City, Iowa
- Clinical & Translational Science Unit (CTSU) - Nephrology — Kansas City, Kansas
- University of Maryland Medical Center - General Clinical Research Center — Baltimore, Maryland
- Tufts Medical Center — Boston, Massachusetts
- Beth Israel Deaconess Medical Center - Nephrology — Boston, Massachusetts
- University of Minnesota -Clinics and Surgery Center (CSC) - Endocrine Clinic — Minneapolis, Minnesota
- Mayo Clinic - Rochester — Rochester, Minnesota
- DaVita Kidney Care - Las Vegas — Las Vegas, Nevada
- The Rogosin Kidney Center — New York, New York
- General Nephrology Clinic - New York City — New York, New York
- Cleveland Clinic - Main Campus — Cleveland, Ohio
- Geisinger Clinic — Danville, Pennsylvania
- Perelman Center for Advanced Medicine - Nephrology — Philadelphia, Pennsylvania
- Nephrology Clinical Trials Center — Nashville, Tennessee
- UVM Medical Center - 1 South Prospect Street — Burlington, Vermont
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease — Alabaster, Alabama
- Di-PKD: A Pilot Trial of Dietary Intervention in Patients With Autosomal Dominant Polycystic Kidney Disease — Loma Linda, California
- Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease — Cleveland, Ohio
Explore by condition: All Autosomal Dominant Polycystic Kidney Disease (ADPKD) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.